This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Human Immunodeficiency Virus Type 1 (HIV 1) Market

Rise in the prevalence of HIV patients, advanced drugs and vaccines are pushing the market growth

Human Immunodeficiency Virus Type 1 (HIV 1) Market by Drug Class & Region – Forecast 2023–2033

Human Immunodeficiency Virus Type 1 (HIV 1) Market Snapshot (2023-2033)

The global human immunodeficiency virus type 1 (HIV 1) market size is expected to reach a valuation of US$ 34.83 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033.

HIV is a virus target the body's cells that aid in the battle against infectious disease, making the individual more sensitive to other illnesses and infections. HIV is a retrovirus comprising RNA rather than DNA. It attacks the immune system (T lymphocytes and other white blood cells with CD4 receptors on their surfaces) in the body.

According to the Institute for Health Metrics and Evaluation, the market's expansion can be attributed to the rising incidence rate of HIV-1 infection, which, unlike the fatality rate from this viral illness, has not updated significantly over the years. It affected approximately 37 million individuals around the world. Moreover, only half of this population has access to antiretroviral therapeutic interventions for disease control. HIV-1 is the more frequent of the two varieties of the human immunodeficiency virus, accounting for roughly 96% of all infections worldwide. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute

Details

Expected Market Value (2023)

US$ 34.83 Billion

Anticipated Forecast Value (2033)

US$ 62.37 Billion

Projected Growth Rate (2023-2033)

6% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2018-2022 Human Immunodeficiency Virus Type 1 (HIV 1) Demand Analysis vs. Forecast 2023-2033

The global population of individuals infected with this virus rapidly increased during the historical period. As a result of the lack of sufficient diagnosis and treatment infrastructure, the disease has heavily impacted poor and developing countries on a wide scale. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.6%.

The incidence of HIV is soaring at an alarming rate. Based on the World Health Organization (WHO), a guesstimated 33.0 million people are infected with HIV. This has resulted in higher public awareness, which is leading to a rise in test methods. Over the forecast period, this will result in an increase in demand for HIV medicines with higher efficacy for the treatment and care of the disease.

Which are Some Prominent Drivers of the Human Immunodeficiency Virus Type 1 (HIV 1) Market?

Burgeoning HIV/AIDS Incidence to Push Market Growth

One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 33.0 million people were living with HIV infection in 2021, with 1.5 million [1.1 million-2.0 million] new HIV infections.

According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV 1 patients' access to treatment and assessment. This is expected to fuel the global HIV 1 market.

Combined efforts of the government and several NGOs to propel the market growth

The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.

Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Scarcity of Treatment Access and Lack of awareness of HIV Infection Status May Stifle Growth

Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.

As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.

Region-Wise Insights

What Makes North America the Largest Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

North America's dominance is due to the high prevalence of HIV infection

With a market share of US$ 21 Billion in 2022, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people were living with HIV at the end of 2018.

With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.

Why is Asia Pacific Considered a Lucrative Region for the Human Immunodeficiency Virus Type 1 (HIV 1) Market?

Because of its dense population, the Asia Pacific market is the fastest-growing region

Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.

For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a US$ 1.4 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2020. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

Which Type Leads the Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients

As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2021, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).

The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the lately innovative pharmaceutical launches

Start-ups in the HIV 1 Treatment Domain

  • Y Combinator is a technology start-up activator in the United States that was founded in March 2005. The Immunity Project is creating a free HIV/AIDS vaccine using a novel approach involving data analysis and machine learning. It is one of seven charitable organizations in the current batch of the elite accelerator program Y Combinator.
  • Argu Soft India Limited is a start-up company that was founded on August 21, 2000. It is headquartered in Gandhi Nagar, Gujarat, India. ArguSoft developed a health app to inhibit AIDS transmission from mother to child and is collaborating with the Indian government and charitable groups to combat the disease efficaciously.

Market Competition

Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

  • In July 2021 - Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) declared a pricing contract with the medical company Hetero Labs LTD to create darunavir combined with ritonavir (DRV/r) obtainable as a second-line treatment for HIV patients in low and moderate-income nations for US$ 210 per patient/year.
  • Gilead Sciences Inc. and Merck revealed a partnership deal in March 2021 to co-develop and co-commercialize lengthy HIV treatment. Gilead's investigational capsid inhibitor lenacapavir and Merck's investigational nucleoside reverse transcriptase translocation inhibitor islatravir will be combined to produce a two-drug regimen for HIV.
  • In January 2021 - HIV Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults, was developed by ViiV Healthcare.

Report Scope

Report Attribute

Details

Expected Market Value (2023)

US$ 34.83 Billion

Anticipated Forecast Value (2033)

US$ 62.37 Billion

Projected Growth Rate (2023-2033)

6% CAGR

Base Year for Estimation

2022

Historical Data

2018-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Class
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Russia
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Saudi Arabia
  • South Africa
  • U.A.E
  • Israel

Key Companies Profiled

  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Genentech Inc.
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • ViiV Healthcare
  • GlaxoSmithKline
  • Sanofi

Customization

Available Upon Request

Key Segments Profiled in the Human Immunodeficiency Virus Type 1 (HIV 1) Market Industry Survey

Human Immunodeficiency Virus Type 1 (HIV 1) Market by Drug Class:

  • Nucleoside-Analog Reverse Transcriptase Inhibitor
  • Non-Nucleoside Reverse Transcriptase Inhibitor
  • Entry and Fusion Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • Coreceptor Antagonists

Human Immunodeficiency Virus Type 1 (HIV 1) Market by Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

FMI projects the global Human Immunodeficiency Virus Type 1 (HIV 1) market to expand at a 6% value CAGR by 2033.

The global Human Immunodeficiency Virus Type 1 (HIV 1) market is estimated at a market value of US$ 34.83 Billion.

The global Human Immunodeficiency Virus Type 1 (HIV 1) market is expected to garner a market value of US$ 62.37 Billion

FMI has projected Asia Pacific to be one of the key regions for the Human Immunodeficiency Virus Type 1 (HIV 1) market.

AbbVie, Inc, Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline and Sanofi.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Investment Feasibility Matrix

    3.6. PESTLE and Porter’s Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033

        5.3.1. Nucleoside-Analog Reverse Transcriptase Inhibitors

        5.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors

        5.3.3. Entry and Fusion Inhibitors

        5.3.4. Protease Inhibitors

        5.3.5. Integrase Inhibitors

        5.3.6. Coreceptor Antagonists

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    6.1. Introduction

    6.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    6.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        6.3.1. North America

        6.3.2. Latin America

        6.3.3. Europe

        6.3.4. Asia Pacific

        6.3.5. Middle East and Africa

    6.4. Market Attractiveness Analysis By Region

7. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    7.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    7.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        7.2.1. By Country

            7.2.1.1. U.S.

            7.2.1.2. Canada

        7.2.2. By Drug Class

    7.3. Market Attractiveness Analysis

        7.3.1. By Country

        7.3.2. By Drug Class

    7.4. Key Takeaways

8. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        8.2.1. By Country

            8.2.1.1. Brazil

            8.2.1.2. Mexico

            8.2.1.3. Rest of Latin America

        8.2.2. By Drug Class

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

    8.4. Key Takeaways

9. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        9.2.1. By Country

            9.2.1.1. Germany

            9.2.1.2. U.K.

            9.2.1.3. France

            9.2.1.4. Spain

            9.2.1.5. Italy

            9.2.1.6. Russia

            9.2.1.7. Rest of Europe

        9.2.2. By Drug Class

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

    9.4. Key Takeaways

10. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. China

            10.2.1.2. Japan

            10.2.1.3. India

            10.2.1.4. South Korea

            10.2.1.5. Australia

            10.2.1.6. Rest of APAC

        10.2.2. By Drug Class

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

    10.4. Key Takeaways

11. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. South Africa

            11.2.1.2. Saudi Arabia

            11.2.1.3. UAE

            11.2.1.4. Israel

            11.2.1.5. Rest of MEA

        11.2.2. By Drug Class

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

    11.4. Key Takeaways

12. Key Countries Market Analysis

    12.1. U.S.

        12.1.1. Pricing Analysis

        12.1.2. Market Share Analysis, 2022

            12.1.2.1. By Drug Class

    12.2. Canada

        12.2.1. Pricing Analysis

        12.2.2. Market Share Analysis, 2022

            12.2.2.1. By Drug Class

    12.3. Brazil

        12.3.1. Pricing Analysis

        12.3.2. Market Share Analysis, 2022

            12.3.2.1. By Drug Class

    12.4. Mexico

        12.4.1. Pricing Analysis

        12.4.2. Market Share Analysis, 2022

            12.4.2.1. By Drug Class

    12.5. Germany

        12.5.1. Pricing Analysis

        12.5.2. Market Share Analysis, 2022

            12.5.2.1. By Drug Class

    12.6. U.K.

        12.6.1. Pricing Analysis

        12.6.2. Market Share Analysis, 2022

            12.6.2.1. By Drug Class

    12.7. France

        12.7.1. Pricing Analysis

        12.7.2. Market Share Analysis, 2022

            12.7.2.1. By Drug Class

    12.8. Spain

        12.8.1. Pricing Analysis

        12.8.2. Market Share Analysis, 2022

            12.8.2.1. By Drug Class

    12.9. Italy

        12.9.1. Pricing Analysis

        12.9.2. Market Share Analysis, 2022

            12.9.2.1. By Drug Class

    12.10. Russia

        12.10.1. Pricing Analysis

        12.10.2. Market Share Analysis, 2022

            12.10.2.1. By Drug Class

    12.11. China

        12.11.1. Pricing Analysis

        12.11.2. Market Share Analysis, 2022

            12.11.2.1. By Drug Class

    12.12. Japan

        12.12.1. Pricing Analysis

        12.12.2. Market Share Analysis, 2022

            12.12.2.1. By Drug Class

    12.13. India

        12.13.1. Pricing Analysis

        12.13.2. Market Share Analysis, 2022

            12.13.2.1. By Drug Class

    12.14. South Korea

        12.14.1. Pricing Analysis

        12.14.2. Market Share Analysis, 2022

            12.14.2.1. By Drug Class

    12.15. Australia

        12.15.1. Pricing Analysis

        12.15.2. Market Share Analysis, 2022

            12.15.2.1. By Drug Class

    12.16. South Africa

        12.16.1. Pricing Analysis

        12.16.2. Market Share Analysis, 2022

            12.16.2.1. By Drug Class

    12.17. Saudi Arabia

        12.17.1. Pricing Analysis

        12.17.2. Market Share Analysis, 2022

            12.17.2.1. By Drug Class

    12.18. UAE

        12.18.1. Pricing Analysis

        12.18.2. Market Share Analysis, 2022

            12.18.2.1. By Drug Class

    12.19. Israel

        12.19.1. Pricing Analysis

        12.19.2. Market Share Analysis, 2022

            12.19.2.1. By Drug Class

13. Market Structure Analysis

    13.1. Competition Dashboard

    13.2. Competition Benchmarking

    13.3. Market Share Analysis of Top Players

        13.3.1. By Regional

        13.3.2. By Drug Class

14. Competition Analysis

    14.1. Competition Deep Dive

        14.1.1. AbbVie, Inc.

            14.1.1.1. Overview

            14.1.1.2. Product Portfolio

            14.1.1.3. Profitability by Market Segments

            14.1.1.4. Sales Footprint

            14.1.1.5. Strategy Overview

                14.1.1.5.1. Marketing Strategy

        14.1.2. Boehringer Ingelheim GmbH

            14.1.2.1. Overview

            14.1.2.2. Product Portfolio

            14.1.2.3. Profitability by Market Segments

            14.1.2.4. Sales Footprint

            14.1.2.5. Strategy Overview

                14.1.2.5.1. Marketing Strategy

        14.1.3. Bristol-Myers Squibb Company

            14.1.3.1. Overview

            14.1.3.2. Product Portfolio

            14.1.3.3. Profitability by Market Segments

            14.1.3.4. Sales Footprint

            14.1.3.5. Strategy Overview

                14.1.3.5.1. Marketing Strategy

        14.1.4. Cipla, Inc.

            14.1.4.1. Overview

            14.1.4.2. Product Portfolio

            14.1.4.3. Profitability by Market Segments

            14.1.4.4. Sales Footprint

            14.1.4.5. Strategy Overview

                14.1.4.5.1. Marketing Strategy

        14.1.5. Genentech, Inc.

            14.1.5.1. Overview

            14.1.5.2. Product Portfolio

            14.1.5.3. Profitability by Market Segments

            14.1.5.4. Sales Footprint

            14.1.5.5. Strategy Overview

                14.1.5.5.1. Marketing Strategy

        14.1.6. Gilead Sciences, Inc.

            14.1.6.1. Overview

            14.1.6.2. Product Portfolio

            14.1.6.3. Profitability by Market Segments

            14.1.6.4. Sales Footprint

            14.1.6.5. Strategy Overview

                14.1.6.5.1. Marketing Strategy

        14.1.7. Merck & Co., Inc.

            14.1.7.1. Overview

            14.1.7.2. Product Portfolio

            14.1.7.3. Profitability by Market Segments

            14.1.7.4. Sales Footprint

            14.1.7.5. Strategy Overview

                14.1.7.5.1. Marketing Strategy

        14.1.8. ViiV Healthcare

            14.1.8.1. Overview

            14.1.8.2. Product Portfolio

            14.1.8.3. Profitability by Market Segments

            14.1.8.4. Sales Footprint

            14.1.8.5. Strategy Overview

                14.1.8.5.1. Marketing Strategy

        14.1.9. GlaxoSmithKline

            14.1.9.1. Overview

            14.1.9.2. Product Portfolio

            14.1.9.3. Profitability by Market Segments

            14.1.9.4. Sales Footprint

            14.1.9.5. Strategy Overview

                14.1.9.5.1. Marketing Strategy

        14.1.10. Sanofi

            14.1.10.1. Overview

            14.1.10.2. Product Portfolio

            14.1.10.3. Profitability by Market Segments

            14.1.10.4. Sales Footprint

            14.1.10.5. Strategy Overview

                14.1.10.5.1. Marketing Strategy

15. Assumptions & Acronyms Used

16. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Table 3: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 4: North America Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Table 5: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 6: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Table 7: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 8: Europe Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Table 9: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 10: Asia Pacific Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Table 11: Middle East and Africa Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 12: Middle East and Africa Market Value (US$ Mn) Forecast by Drug Class, 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 3: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 6: Global Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 9: Global Market Attractiveness by Drug Class, 2023-2033

Figure 10: Global Market Attractiveness by Region, 2023-2033

Figure 11: North America Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 12: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 13: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 16: North America Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 17: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 18: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 19: North America Market Attractiveness by Drug Class, 2023-2033

Figure 20: North America Market Attractiveness by Country, 2023-2033

Figure 21: Latin America Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 22: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 23: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 26: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 27: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 29: Latin America Market Attractiveness by Drug Class, 2023-2033

Figure 30: Latin America Market Attractiveness by Country, 2023-2033

Figure 31: Europe Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 32: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 33: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 34: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 35: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 36: Europe Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 37: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 38: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 39: Europe Market Attractiveness by Drug Class, 2023-2033

Figure 40: Europe Market Attractiveness by Country, 2023-2033

Figure 41: Asia Pacific Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 42: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 43: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 44: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 45: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 46: Asia Pacific Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 47: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 48: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 49: Asia Pacific Market Attractiveness by Drug Class, 2023-2033

Figure 50: Asia Pacific Market Attractiveness by Country, 2023-2033

Figure 51: Middle East and Africa Market Value (US$ Mn) by Drug Class, 2023-2033

Figure 52: Middle East and Africa Market Value (US$ Mn) by Country, 2023-2033

Figure 53: Middle East and Africa Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 54: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 55: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis by Drug Class, 2018-2033

Figure 57: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033

Figure 58: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033

Figure 59: Middle East and Africa Market Attractiveness by Drug Class, 2023-2033

Figure 60: Middle East and Africa Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

HIV Antivirals Market

Published : June 2022

Healthcare

HIV Diagnostics Market

Published : May 2022

Healthcare

HIV/HBV/HCV Test Kits Market

Published : February 2022

Healthcare

Prophylactic HIV drugs Market

Published : June 2019

Google translate

Human Immunodeficiency Virus Type 1 (HIV 1) Market